ECM
RGNX icon

Endurant Capital Management’s Regenxbio RGNX Stock Holding History

Endurant Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-36,000
Closed -$711K – 99
2017
Q2 		$711K Buy
36,000
+11,200
+45% +$217K 0.2% 78
2017
Q1 		$479K Buy
+24,800
New +$478K 0.15% 78
2016
Q4 		– Sell
-12,026
Closed -$168K – 85
2016
Q3 		$168K Buy
+12,026
New +$133K 0.06% 94

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Endurant Capital Management's RGNX Position: Q3 2017 in Review

Endurant Capital Management sold out of Regenxbio (RGNX) in Q3 2017, closing a stake of 36,000 shares — an estimated $711K sold.

Endurant Capital Management first reported a position in RGNX in Q3 2016 and held it in 3 quarters. The position peaked at $711K in Q2 2017. 89 funds tracked by Wall St. Rank hold RGNX as of Q3 2017.

  • Endurant Capital Management reported no remaining Regenxbio position as of Q3 2017 after selling out during the quarter.
  • Endurant Capital Management sold 36,000 Regenxbio shares in Q3 2017, an estimated $711K.
  • Endurant Capital Management first reported a position in Regenxbio in Q3 2016 and held it in 3 quarters.
  • Endurant Capital Management's Regenxbio position peaked at $711K in Q2 2017.
  • 89 funds tracked by Wall St. Rank held Regenxbio as of Q3 2017.

Based on Endurant Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.